A share price of Cytokinetics Inc [CYTK] is currently trading at $38.72, up 4.99%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CYTK shares have gain 9.84% over the last week, with a monthly amount glided 0.10%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Barclays started tracking the stock with Overweight rating on April 24, 2025, and set its price target to $55. On February 07, 2025, Citigroup initiated with a Buy rating and assigned a price target of $86 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $80 on January 22, 2025. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $80 as its price target on November 08, 2024. Goldman downgraded its rating to Neutral for this stock on August 13, 2024, and downed its price target to $60. In a note dated January 24, 2024, UBS downgraded an Neutral rating on this stock and boosted its target price from $61 to $92.
Cytokinetics Inc experienced fluctuations in its stock price throughout the past year between $29.31 and $59.39. Currently, Wall Street analysts expect the stock to reach $61 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $38.72 at the most recent close of the market. An investor can expect a potential return of 57.54% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
Trailing Twelve Months sales for Cytokinetics Inc [NASDAQ:CYTK] were 85.74M which represents 26714.86% growth. Gross Profit Margin for this corporation currently stands at -2.27% with Operating Profit Margin at -6.38%, Pretax Profit Margin comes in at -7.07%, and Net Profit Margin reading is -7.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is 3.09 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.97 points at the first support level, and at 35.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 39.63, and for the 2nd resistance point, it is at 40.55.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cytokinetics Inc [NASDAQ:CYTK] is 6.76. As well, the Quick Ratio is 6.76, while the Cash Ratio is 0.57. Considering the valuation of this stock, the price to sales ratio is 54.04.
Transactions by insiders
Recent insider trading involved Malik Fady Ibraham, EVP Research & Development, that happened on Aug 05 ’25 when 2000.0 shares were sold. President & CEO, Blum Robert I completed a deal on Jul 29 ’25 to sell 5000.0 shares. Meanwhile, EVP Research & Development Malik Fady Ibraham sold 2000.0 shares on Jul 22 ’25.
